Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience Corporation (NASDAQ: TWST) announced a partnership with Berry Genomics, a leading next-generation sequencing (NGS) provider in China. This collaboration will integrate Twist’s NGS target enrichment and library preparation tools into Berry’s offerings, enhancing the capability to diagnose cancer and genetic diseases. The partnership emphasizes high-quality NGS panels and continuous development of diagnostic solutions. Dr. Emily M. Leproust, CEO of Twist, highlighted the importance of this collaboration for precision medicine in China.
Twist Bioscience Corporation (NASDAQ: TWST) has announced that CEO Emily Leproust, Ph.D., and CFO Jim Thorburn will present at several virtual investor conferences. The presentations include the SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 11:20 a.m. ET, the Cowen 41st Annual Healthcare Conference on March 4 at 1:30 p.m. ET, and the Barclays Global Healthcare Conference on March 9 at 10:20 a.m. ET. These fireside chats will be webcast live and available for 30 days afterwards. Twist Bioscience is known for its innovative synthetic DNA technology.
Twist Bioscience (NASDAQ: TWST) and Victorian Clinical Genetic Services (VCGS) have collaborated to create a novel whole exome capture assay utilizing Next Generation Sequencing (NGS). This assay enhances diagnostics and carrier screening by enabling comprehensive analysis of clinically relevant regions with minimal gaps. VCGS, accredited for in vitro diagnostics, will utilize this advanced assay for patient management. Twist's Comprehensive Exome Assay covers over 99% of protein-coding genes, facilitating improved variant detection and customization capabilities, thus delivering high-quality, actionable genetic data.
Twist Bioscience (NASDAQ: TWST) reported strong financial results for Q1 FY2021, with total orders reaching $33.6 million, up from $24.8 million a year prior. Revenue increased to $28.2 million, compared to $17.2 million in Q1 FY2020. Although the net loss narrowed to $32.9 million (or $0.72 per share), up from $55.6 million (or $1.69 per share) year-over-year, the company strengthened its balance sheet with $324 million raised through an equity offering. Future growth is anticipated with the launch of new products and expansion of manufacturing capabilities.
Twist Bioscience Corporation (NASDAQ: TWST) announced senior management promotions and team expansion to support its growth and leadership. Key promotions include Siyuan Chen as Chief Technology Officer, Aaron Sato as Chief Scientific Officer, and Paula Green as Senior Vice President of Human Resources. Angela Bitting joins as Senior Vice President of Corporate Affairs, enhancing investor relations and internal communications. This strategic move aims to bolster Twist's position in synthetic DNA manufacturing and the development of products across various industries.
Twist Bioscience (NASDAQ: TWST) will announce its fiscal 2021 first-quarter financial results on February 4, 2020, after market close. A conference call for analysts and investors will take place at 4:30 p.m. ET to discuss these results. Twist Bioscience specializes in high-quality synthetic DNA production using its innovative silicon platform, catering to multiple industries including healthcare and agriculture. The company is focused on expanding its DNA synthesis capabilities and exploring opportunities in digital data storage and biologics.
Twist Bioscience (NASDAQ: TWST) announced two licensing agreements through its Twist Biopharma division with Serotiny and Applied StemCell. The collaboration with Serotiny focuses on discovering novel Chimeric Antigen Receptors (CARs) for CAR T-Cell therapies, while the agreement with Applied StemCell involves using the TARGATT™ CHO Cell Technology for antibody therapeutics. Both partnerships aim to enhance Twist Biopharma's capabilities in developing novel therapies, potentially transforming treatment for challenging cancers.
Twist Bioscience Corporation (Nasdaq: TWST) has started shipping new synthetic RNA reference controls, including the SARS-CoV-2 variant strain B1.1.7. This strain's mutations may result in false negative COVID-19 test results due to some RT-PCR probes failing to detect the S gene. CEO Emily M. Leproust stated these controls help customers update testing protocols to reduce false negatives. Twist's controls support monitoring viral evolution and are used globally in various assays, demonstrating its commitment to improving health outcomes.
On January 11, 2021, ScanlanKemperBard (SKB), the General Partner of PW Venture Portland Limited Partnership, announced a significant lease agreement with Twist Bioscience Corporation (NASDAQ: TWST) at ParkWorks Industry Center in Wilsonville, Oregon. Twist has signed a lease for 110,000 square feet, marking the first lease executed since SKB acquired the property in April 2020. The deal is anticipated to enhance interest from life science and tech-manufacturing tenants as SKB implements extensive capital improvements to the facility.
Twist Bioscience (Nasdaq: TWST) has partnered with the CDC to provide customized SARS-CoV-2 Synthetic RNA Controls for the Flu SC2 Multiplex Assay, which tests for influenza and COVID-19. These positive controls enhance quality assurance for next-generation sequencing and RT-PCR assays. The CDC plans to utilize this assay across U.S. public health laboratories. Twist's CEO emphasized the optimization of these controls for stability at room temperature. This initiative reflects Twist's commitment to advancing public health through innovative solutions in bioscience.
